Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, Oct. 15, 2013, 94 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $5.48 to $122,908,412.25.
Highlighted Stocks Traded by Insiders:
Ciena Corporation (CIEN) - FREE Research Report Claflin Bruce L. who is Director at Ciena Corporation sold 400 shares at $26.14 on Oct. 15, 2013. Following this transaction, the Director owned 48,914 shares meaning that the stake was reduced by 0.81% with the 400 share transaction.
The shares most recently traded at $27.19, up $1.05, or 3.86% since the insider transaction. Historical insider transactions for Ciena Corporation go as follows:
- 4-Week # shares sold: 52,840
- 12-Week # shares sold: 87,640
- 24-Week # shares sold: 225,079
The average volume for Ciena Corporation has been 3.5 million shares per day over the past 30 days. Ciena Corporation has a market cap of $2.6 billion and is part of the technology sector and telecommunications industry. Shares are up 60% year to date as of the close of trading on Friday.
Ciena Corporation provides communications networking equipment, software, and services that support the transport, switching, aggregation, and management of voice, video, and data traffic worldwide. Currently there are 12 analysts that rate Ciena Corporation a buy, no analysts rate it a sell, and 5 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on CIEN - FREE TheStreet Quant Ratings rates Ciena Corporation as a
hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share and increase in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full
Ciena Corporation Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
AutoZone (AZO) - FREE Research Report Brooks Douglas H who is Director at AutoZone bought 355 shares at $422.54 on Oct. 15, 2013. Following this transaction, the Director owned 514 shares meaning that the stake was reduced by 223.27% with the 355 share transaction.
The shares most recently traded at $419.83, down $2.71, or 0.65% since the insider transaction. Historical insider transactions for AutoZone go as follows:
- 4-Week # shares sold: 557
- 12-Week # shares sold: 557
- 24-Week # shares sold: 557
The average volume for AutoZone has been 231,800 shares per day over the past 30 days. AutoZone has a market cap of $14.7 billion and is part of the services sector and retail industry. Shares are up 16.89% year to date as of the close of trading on Friday.
AutoZone, Inc. engages in retailing and distributing automotive replacement parts and accessories. The company has a P/E ratio of 16.0. Currently there are 8 analysts that rate AutoZone a buy, 1 analyst rates it a sell, and 6 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on AZO - FREE TheStreet Quant Ratings rates AutoZone as a
buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, revenue growth, increase in stock price during the past year, expanding profit margins and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full
AutoZone Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Heartland Payment Systems (HPY) - FREE Research Report Drysdale Ian who is President-Network Solutions at Heartland Payment Systems sold 3,156 shares at $39.90 on Oct. 15, 2013. Following this transaction, the President-Network Solutions owned 4,000 shares meaning that the stake was reduced by 44.1% with the 3,156 share transaction.
The shares most recently traded at $38.76, down $1.14, or 2.94% since the insider transaction. Historical insider transactions for Heartland Payment Systems go as follows:
- 4-Week # shares sold: 3,000
- 12-Week # shares sold: 47,129
- 24-Week # shares sold: 55,638
The average volume for Heartland Payment Systems has been 311,700 shares per day over the past 30 days. Heartland Payment Systems has a market cap of $1.4 billion and is part of the services sector and diversified services industry. Shares are up 32.47% year to date as of the close of trading on Friday.
Heartland Payment Systems, Inc. provides bankcard payment processing services in the United States and Canada. The stock currently has a dividend yield of 0.72%. The company has a P/E ratio of 22.1. Currently there are 8 analysts that rate Heartland Payment Systems a buy, 1 analyst rates it a sell, and 4 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on HPY - FREE TheStreet Quant Ratings rates Heartland Payment Systems as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, good cash flow from operations, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full
Heartland Payment Systems Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
MSC Industrial Direct (MSM) - FREE Research Report Kelly Denis F who is Director at MSC Industrial Direct sold 5,000 shares at $69.84 on Oct. 15, 2013. Following this transaction, the Director owned 8,687 shares meaning that the stake was reduced by 36.53% with the 5,000 share transaction.
The shares most recently traded at $82.05, up $12.21, or 14.88% since the insider transaction. Historical insider transactions for MSC Industrial Direct go as follows:
- 12-Week # shares sold: 2,760
- 24-Week # shares sold: 214,612
The average volume for MSC Industrial Direct has been 284,500 shares per day over the past 30 days. MSC Industrial Direct has a market cap of $4.0 billion and is part of the services sector and wholesale industry. Shares are up 6.89% year to date as of the close of trading on Friday.
MSC Industrial Direct Co., Inc., together with its subsidiaries, operates as a direct marketer and distributor of metalworking and maintenance, repair, and operations (MRO) products to industrial customers in the United States. The stock currently has a dividend yield of 1.49%. The company has a P/E ratio of 20.4. Currently there are 6 analysts that rate MSC Industrial Direct a buy, no analysts rate it a sell, and 7 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on MSM - FREE TheStreet Quant Ratings rates MSC Industrial Direct as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
MSC Industrial Direct Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Biomarin Pharmaceutical (BMRN) - FREE Research Report Bienaime Jean Jacques who is Chief Executive Officer at Biomarin Pharmaceutical sold 3,000 shares at $66.76 on Oct. 15, 2013. Following this transaction, the Chief Executive Officer owned 45,740 shares meaning that the stake was reduced by 6.16% with the 3,000 share transaction.
The shares most recently traded at $72.33, up $5.57, or 7.7% since the insider transaction. Historical insider transactions for Biomarin Pharmaceutical go as follows:
- 12-Week # shares sold: 4,066
- 24-Week # shares sold: 36,416
The average volume for Biomarin Pharmaceutical has been 1.4 million shares per day over the past 30 days. Biomarin Pharmaceutical has a market cap of $10.3 billion and is part of the health care sector and drugs industry. Shares are up 49.61% year to date as of the close of trading on Friday.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently there are 10 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 4 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on BMRN - FREE TheStreet Quant Ratings rates Biomarin Pharmaceutical as a
hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and feeble growth in the company's earnings per share. Get the full
Biomarin Pharmaceutical Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. Data for this article provided by
Zacks Investment Research
